Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Analysts bullish on Alto Neuroscience

Published 27/02/2024, 17:12
Updated 27/02/2024, 17:12
© Reuters.

Alto Neuroscience (ANRO) was initiated with bullish ratings at Jefferies (Buy), TD Cowen (Outperform), Baird (Outperform), and Stifel (Buy) in research notes Tuesday.

Jefferies analysts, who assigned the stock a $33 price target, said they like the risk/reward into four Phase II depression/schizophrenia readouts in H2:24/2025. Analysts added that just one study needs to succeed for significant value creation.

TD Cowen stated the company is "redefining psychiatry with precision." They stated: "ANRO is developing precision neuropsychiatry therapies for MDD, PTSD, and schizophrenia. We think the most current investment value resides in the lead Ph2b asset."

Baird, which has a $32 price target on the stock, argues that Alto is taking a forward-thinking approach to the MDD space and other neuropsych indications.

"We think the key Phase 2b readouts from ALTO-100 and ALTO-300 in their respective MDD subpopulations in 2H24 and 1H25, respectively, carry substantial upside potential for shares," analysts wrote.

Stifel, which also assigned ANRO with a $32 price target, explained that ANRO is "leveraging a 'precision psychiatry' approach in the development of various early-to-mid-stage CNS drug candidates."

"In theory, the idea of precision psychiatry makes a ton of sense," analysts wrote. "It's well accepted that conditions like depression, bipolar and anxiety are highly heterogeneous, and KOLs are very receptive to the idea of leveraging biomarkers."

"In our view, each asset offers a credible shot-on-goal on the back of promising initial data--with a highly upside biased stock risk/reward into 2H24/1H25 readouts," analysts wrote.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.